Moderna Shares Rise 3.7% Pre-Market Amid $2.25 Billion Patent Settlement

Moderna's stock saw a 3.7% increase in pre-market trading following the announcement of a significant settlement. According to Jin10, the company has agreed to pay up to $2.25 billion to resolve a patent dispute related to its COVID-19 vaccine. This settlement marks a crucial step for Moderna in addressing ongoing legal challenges surrounding its vaccine technology. The resolution of this patent issue is expected to have a positive impact on the company's financial outlook and investor confidence.